# TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))

> **NCT06169722** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Tide Pharmaceutical Co., Ltd** · enrollment: 60 (estimated)

## Conditions studied

- GVHD, Chronic

## Interventions

- **DRUG:** TDI01 suspension

## Key facts

- **NCT ID:** NCT06169722
- **Lead sponsor:** Beijing Tide Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-06
- **Primary completion:** 2026-02
- **Final completion:** 2027-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06169722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06169722, "TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06169722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*